Hillchol vaccine
Sponsors
Bharat Biotech International Limited
Conditions
Cholera
Phase 3
A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).
NCT05507229
Start: 2022-02-22End: 2022-10-30Updated: 2022-08-18
To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)
NCT05732766
Start: 2023-02-04End: 2023-08-31Target: 1800Updated: 2023-02-17